Report: Sandoz fights to bring first biosimilar to U.S.

SAN FRANCISCO — Sandoz argued before the U.S Court of Appeals for the Federal Circuit Wednesday in an effort to lift a preliminary injunction barring the sale of its Zarxio biosimilar medicine, Reuters reported. 

 

Amgen, the maker of Neupogen, sued to have Zarxio barred from the market this past fall for patent infringement. 

 

According to Reuters, if the injunction were to be lifted, Zarxio would become the first biosimilar sold in the United States.